Cargando…
Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond
Current therapy for Anderson–Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the...
Autores principales: | Nowicki, Michał, Bazan-Socha, Stanisława, Kłopotowski, Mariusz, Błażejewska-Hyżorek, Beata, Kusztal, Mariusz, Pawlaczyk, Krzysztof, Sławek, Jarosław, Oko, Andrzej, Oko-Sarnowska, Zofia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394954/ https://www.ncbi.nlm.nih.gov/pubmed/34443990 http://dx.doi.org/10.3390/ijerph18168242 |
Ejemplares similares
-
First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland
por: Nowicki, Michał, et al.
Publicado: (2021) -
Supporting the Diagnosis of Fabry Disease Using a Natural Language Processing-Based Approach
por: Michalski, Adrian A., et al.
Publicado: (2023) -
Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles
por: Trojnarska, Olga, et al.
Publicado: (2010) -
Fabry disease and sleep disorders: a systematic review
por: Blaszczyk, Bartlomiej, et al.
Publicado: (2023) -
Abnormal Nailfold Capillaries in Patients after Hand Transplantation
por: Sikorska, Dorota, et al.
Publicado: (2020)